Johnson & Johnson to acquire Intra-Cellular Therapies in $14.6bn deal
Johnson & Johnson has announced its largest biotech acquisition in over a year, agreeing to purchase Intra-Cellular Therapies for $14.6 billion. The deal highlights the ... Read More
Neumora Therapeutics’ KOASTAL-1 study of navacaprant for MDD falls short on primary endpoint
Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company specialising in neuroscience, has announced results from the KOASTAL-1 Phase 3 study evaluating navacaprant as a ... Read More
Suven Life Sciences reveals breakthrough with Ropanicant in depression treatment
Suven Life Sciences Limited has made a significant advancement in the fight against depression, announcing positive results from a Phase-2a proof-of-concept study involving Ropanicant (SUVN-911). ... Read More
Johnson & Johnson seeks FDA approval for SPRAVATO in treatment-resistant depression
Johnson & Johnson (NYSE: JNJ) is seeking U.S. Food and Drug Administration (FDA) approval for SPRAVATO (esketamine) as a standalone treatment for adults with treatment-resistant ... Read More
Sage Therapeutics, Biogen get ZURZUVAE FDA approval for postpartum depression treatment
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE (zuranolone) 50 mg for adults ... Read More
Granules India gets Venlafaxine ER Capsules FDA approval
Granules India has secured approval for its abbreviated new drug application (ANDA) for Venlafaxine Hydrochloride Extended-Release (ER) Capsules USP, 37.5 mg, 75 mg, and 150 ... Read More
Digital medicine firm Akili Interactive to merge with Social Capital Suvretta
Akili Interactive, a US-based digital medicine company, has agreed to merge with Social Capital Suvretta Holdings Corp. I (SCS), a special purpose acquisition company (SPAC), ... Read More
Sage Therapeutics strikes $3.1bn licensing deal with biogen for depression and neurological disorder treatments
Sage Therapeutics has entered into a high-stakes global collaboration and licensing agreement with Biogen, valued at up to $3.1 billion, aimed at advancing two promising ... Read More
Tenzing to acquire clinical-stage pharma company Reviva Pharmaceuticals
Tenzing Acquisition has agreed to acquire Reviva Pharmaceuticals, a California-based clinical-stage pharma company, focused on developing therapies for addressing unmet medical needs in the areas ... Read More
Usona Institute gets FDA breakthrough status for psilocybin in MDD
Wisconsin-based Usona Institute has been granted breakthrough therapy designation for psilocybin from the US Food and Drug Administration (FDA) for the treatment of major depressive ... Read More